Stryker (NYSE:SYK) updated its FY18 earnings guidance on Tuesday. The company provided EPS guidance of $7.07-7.17 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.13. Stryker also updated its Q1 guidance to $1.57-1.62 EPS.
Several brokerages have commented on SYK. Oppenheimer set a $156.00 price objective on Stryker and gave the company a hold rating in a report on Monday, October 30th. Canaccord Genuity lifted their price target on Stryker from $155.00 to $162.00 and gave the stock a buy rating in a research note on Friday, October 27th. Needham & Company LLC reaffirmed a hold rating on shares of Stryker in a research note on Wednesday, January 17th. Robert W. Baird raised Stryker from a neutral rating to an outperform rating in a research note on Friday, November 24th. Finally, ValuEngine lowered Stryker from a buy rating to a hold rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $162.50.
Stryker (NYSE SYK) traded up $0.45 on Wednesday, reaching $155.01. The company had a trading volume of 701,287 shares, compared to its average volume of 1,431,161. The firm has a market cap of $58,010.00, a PE ratio of 57.84, a price-to-earnings-growth ratio of 2.21 and a beta of 0.70. Stryker has a 1 year low of $124.61 and a 1 year high of $170.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59.
Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.78 EPS. equities research analysts anticipate that Stryker will post 7.12 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be given a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.21%. Stryker’s dividend payout ratio (DPR) is presently 70.15%.
In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $164.09, for a total value of $1,214,266.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,840 shares of company stock valued at $2,749,989. Insiders own 7.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Stryker (NYSE:SYK) Issues FY18 Earnings Guidance” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/stryker-syk-issues-fy18-earnings-guidance.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.